核心观点 - KB304在治疗皱纹和改善皮肤弹性方面显示出显著疗效 临床数据显示100%接受KB304治疗的患者在三个月后皱纹改善至少1分 而安慰剂组仅为28.6% [4][5] - 该产品通过基因递送技术直接补充胶原蛋白和弹性蛋白 有望填补市场空白 成为首个针对胸部皱纹的注射类产品 [7][9] - 安全性良好 不良事件均为轻中度 无严重药物相关不良反应报告 [8] 产品技术 - KB304采用HSV-1载体递送COL3和弹性蛋白基因 通过刺激皮肤自身细胞产生这两种蛋白来逆转皮肤衰老 [12] - 产品为直接皮内注射溶液 针对特定美容部位设计 [12] 临床试验结果 - PEARL-2研究为随机双盲安慰剂对照1期试验 共纳入19名受试者 其中12人接受KB304治疗 [4] - 三个月随访显示：研究者评估100%KB304组患者皮肤弹性/水润度/光泽度等指标至少改善1分 安慰剂组无此效果 [6] - 患者自评满意度达81.8% 显著高于安慰剂组的14.3% [5] 研发进展 - 公司已完成胸部专用评分量表(JDWS)开发验证 计划2025年下半年提交FDA并确定2期方案 [9] - 预计2026年上半年启动2期临床试验 将重点开发胸部皱纹适应症 [9] 公司背景 - Jeune为Krystal Biotech全资子公司 专注于利用基因递送平台解决皮肤衰老问题 [14] - 母公司Krystal为商业化阶段生物技术公司 拥有首个可重复给药的基因疗法产品VYJUVEK® [15] 市场沟通 - 公司将于2025年7月24日美东时间16:30召开电话会议讨论研究结果 [1][10] - 会议将通过网络直播进行 录播内容将在官网投资者板块提供 [10][11]

LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum carbonate (OLC) in chronic kidney disease (CKD) patients on dialysis in the Clinical Journal of the American Society of Nephrology. The publication, entitled “A Phase 2 Clinical Tr ...

Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market PotentialSAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, cove ...

收购交易核心条款 - 礼来公司以每股10.50美元现金加最高3美元或有价值权(CVR)的条件收购Verve Therapeutics全部流通股 [1] - 交易包含非交易型或有价值权(CVR)，该权利在达到特定里程碑时支付 [1] - 要约于2025年7月23日美国东部时间23:59到期未延期 [1] 交易执行情况 - 截至到期时间共49,882,464股(占流通股55.7%)被有效投标且未撤回 [2] - 礼来及其全资子公司Ridgeway Acquisition Corporation已接受所有有效投标股份并将及时支付 [2] - 交易预计于2025年7月25日完成 [3] 交易相关方 - 礼来法律顾问为Kirkland & Ellis LLP [3] - Verve财务顾问为Centerview Partners LLC和Guggenheim Securities LLC [3] - Verve法律顾问为Paul, Weiss, Rifkind, Wharton & Garrison LLP [3] Verve Therapeutics业务概况 - 临床阶段基因编辑公司，专注于心血管疾病治疗 [4] - 主要开发单疗程基因编辑药物替代现有慢性疗法 [4] - 三大核心项目分别靶向导致动脉粥样硬化的三种脂蛋白 [4] - VERVE-102靶向PCSK9基因，用于家族性高胆固醇血症和动脉粥样硬化心血管疾病 [4] - VERVE-201靶向ANGPTL3基因，用于难治性高胆固醇血症 [4] - VERVE-301靶向LPA基因，降低脂蛋白(a)水平 [4] 礼来公司业务概况 - 拥有近150年历史的跨国制药企业 [5] - 专注糖尿病、肥胖症、阿尔茨海默病、免疫系统疾病和癌症治疗领域 [5] - 通过生物技术、化学和基因医学推动新药研发 [5]

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestonesMatchpoint will lead all research activities through development candidate selection WATERTOWN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced that it has entered into an exclusive option and lic ...

TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their ...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, Australia and SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an innovative neuroimaging ...

Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year. Others understand that the stock market generates excellent returns over the long run, regardless of short-term uncertainty. I firmly belong to the second camp. The key is to invest in companies that are likely to deliver strong financial results and returns over five years or more. For those who, like me, are still seeking quality stocks to invest in, let's consider two co ...

格隆汇7月24日｜病毒防治股午后进一步拉升，其中，智飞生物涨超16%，沃森生物涨超13%，振东制 药、万孚生物涨超10%，达安基因10CM涨停，康泰生物、康希诺、百克生物、泰林生物、博拓生物等 跟涨。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | --- | | 300122 | 智飞生物 | 1 | 16.86 | 577亿 | -8.29 | | 300142 | 沃森生物 | や | 13.39 | 210亿 | 8.80 | | 300158 | 振东制药 | 1 | 10.70 | 65.55亿 | 50.93 | | 300482 | 万孚生物 | 1 | 10.37 | 120亿 | 13.25 | | 002030 | 达安基因 | -06- | 9.95 | 101亿 | 26.41 | | 000955 | 欣龙控股 | → | 9.92 | 30.42 Z | 36.47 | | 300601 | 康泰生物 | | 8.67 | 197亿 | 3.73 | | 688185 | 康希诺 | + ...

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris *** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Cont ...